Mounjaro and Pancreatitis: What the Evidence Actually Says

The misconception worth clearing up first

A common assumption is that because GLP-1 medicines carry a pancreatitis warning, anyone who has ever had the condition is simply ruled out. That's not quite right, and it's worth setting straight, because it leads some people to either avoid treatment they might safely benefit from, or, in the other direction, to underestimate a genuine safety signal.

The picture is more nuanced. The NHS tirzepatide patient page and Mounjaro's prescribing information both flag pancreatitis as something prescribers must account for, particularly where there is a relevant personal history. Active, ongoing pancreatitis is a clear contraindication, Mounjaro should not be started or continued during an acute episode. A past history, however, is assessed case by case: the severity of previous episodes, how long ago they occurred, the underlying cause, and the overall clinical picture all feed into that decision. No two histories are identical, which is exactly why this is a clinical conversation rather than a checkbox.

You can read more about the broader relationship between tirzepatide and pancreatic effects on our Mounjaro and pancreatitis overview page.

What the MHRA's January 2026 update actually told us

In January 2026 the MHRA published a Drug Safety Update confirming that acute pancreatitis is a known, infrequent adverse effect across the GLP-1 class, Mounjaro included. Infrequent does not mean impossible, and the update was clear that patients and clinicians should remain alert to the symptoms.

The warning sign to take seriously is severe abdominal pain (typically in the upper abdomen) that is persistent, may radiate through to the back, and does not settle on its own. It may or may not come with vomiting. If that pattern develops while you are taking Mounjaro, stop and seek medical attention the same day; do not wait to see if it passes. The MHRA's guidance applies equally whether you have a history of pancreatitis or not, though someone with a prior episode is naturally paying closer attention to how their stomach feels. Our page on whether Mounjaro can cause pancreatitis explains the mechanism and the evidence behind this concern in plain terms.

The full breakdown of pancreatitis risk with Mounjaro covers the clinical evidence in more detail if you want to understand the numbers behind this safety signal.

What a prescriber considers when there is a previous history

If you have had pancreatitis before, a prescriber needs to understand the context before Mounjaro can be considered. Gallstone-related pancreatitis that has been definitively treated is a different situation from recurrent idiopathic pancreatitis or pancreatitis linked to hypertriglyceridaemia, a condition that GLP-1 medicines can actually affect. Alcohol-related episodes add another layer. None of these automatically close the door, but each changes the risk calculation.

The prescriber will also consider the weight-related conditions that make treatment relevant in the first place, for some people, the metabolic benefits of tirzepatide outweigh residual risk once the history is properly understood; for others, an alternative approach makes more sense. That assessment cannot happen without the full picture, which is why this detail must be declared during the consultation, not left out for fear of being turned down.

Details on the specific question of prior episodes are discussed on our page about taking Mounjaro after a previous pancreatitis diagnosis, and on the related history of pancreatitis page.

Other side effects to know, and when to get medical help

Pancreatitis sits at the more serious end of what can happen on Mounjaro, but most people's experience of side effects is far more routine. Nausea, loose stools, constipation, indigestion, and tiredness are the common ones, most noticeable in the first few weeks or after a dose increase, and often settling as the body adjusts. The full side-effect profile page goes through these in detail alongside practical ways to manage them.

Alongside pancreatitis, there are a handful of symptoms that need prompt medical attention rather than a wait-and-see approach: signs of a gallbladder problem (pain in the right upper abdomen, fever, jaundice); severe dehydration from persistent vomiting or diarrhoea; any allergic reaction; and significant changes in mood or thoughts of self-harm, which should prompt a call to a doctor or 111 the same day.

If you want to report a side effect you have experienced (or flag a medicine you think may be counterfeit) the MHRA's Yellow Card scheme is the right place. Reports from patients are taken seriously and feed into ongoing safety monitoring. Our prescribers discuss both suitability and the side-effect profile as part of every consultation; if you have questions before committing, speaking to our clinical team is the right first step.